Company intelligence / Profile preview

Cypherpunk Technologies

Cambridge, Massachusetts, United States

Ownership: Public · CYPH
Employees: ~52
Development stage: Other

Overview

Cypherpunk Technologies develops biomarker-targeted antibody therapies. Its lead candidate DKN-01, a monoclonal antibody inhibiting Dickkopf-related protein 1, is in various ongoing clinical trials for treating esophagogastric, gynecologic, and colorectal cancers. The company also develops FL-501, a monoclonal antibody inhibiting growth differentiation factor 15, currently in preclinical trials.

Therapeutic areas: Oncology
Modalities: Monoclonal antibody
Industry: Biotech

Partnerships

AdimabBeiGene

Financials

Market cap: $280M
Total revenue: $0
Enterprise value: $272.4M

Beyond the preview

Go deeper on Cypherpunk Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cypherpunk Technologies.

Explore the full profile